Introduction
Retinoic acid (RA) controls fundamental developmental processes, induces terminal dierentiation of myeloid progenitors and suppresses cancer and cell growth (Smith et al., 1992; Gudas et al., 1994) . RA activity is mediated by nuclear receptors, the retinoic acid receptors, RARs, that act as RA-dependent transcriptional activators in their heterodimeric forms with retinoid X receptors, RXRs (Chambon, 1996) . RARs induce local chromatin changes at level of target genes, containing responsive RA elements (RAREs) by recruiting multiprotein complexes with histone acetyltransferase (HAT) activity and histone deacetylase (HDAC) activity, that dynamically pattern chromatin modi®ca-tion and regulate gene expression (see for review Chambon, 1996; Minucci and Pelicci, 1999) .
RARs and RXRs, when disrupted, result in severe developmental defects and neoplastic transformation (Smith et al., 1992; Gudas et al., 1994; Chambon, 1996) . In breast cancer cells, the expression of one member of the RARs family, RARb is found consistently downregulated or lost (Roman et al., 1992; Shao et al., 1994; Swisshelm et al., 1994; Li et al., 1995; Widshwendtner et al., 1997; Xu et al., 1997; Liu et al., 1997) . RARb downregulation can be reversed by RA in estrogen receptor (ER)-positive, but not in ER-negative breast carcinoma cell lines, believed to represent more advanced forms of tumors . Loss of RA-induced RARb expression is considered a crucial step in the development of RA-resistance in breast carcinogenesis. A complex regulatory region, with two promoters regulates RARb gene expression. Only one promoter, RARb2, containing several RA-response elements, including a canonical and an auxiliary RA response element, bRARE (de The ' et al., 1990; Valcarel et al., 1994) is active in human mammary epithelial cells (HMEC) . The transcription of the RARb2 promoter is mediated by multiple RARs including, RARa and RARb itself (Chiba et al., 1997) able to recruit coactivator and corepressor protein complexes with HAT/HDAC activities, respectively (Chambon, 1996) . To understand why RARb activity is downregulated, or lost, in breast cancer, intense search has been oriented at identifying possible alterations aecting either the RARb2 promoter, or regulatory factors (Seewaldt et al., 1995; Widschwendtner et al., 1997; Xu et al., 1997; Tsou et al., 1998; Folkers et al., 1998) .
DNA methylation is an epigenetic change that induces chromatin modi®cations and repression of transcription via a methyl CpG binding protein MeCP2, and recruitment of a Sin3A/HDAC corepressor complex (Nan et al., 1998; Wade et al., 1998; Razin, 1998; Ng and Bird, 1999; Jones and Wole, 1999) . For this reason, we decided to investigate whether RARb2 promoter was aected by DNA methylation. Indeed, we found hypermethylation at the RARb2 promoter both in breast carcinoma cell lines, and a signi®cant proportion of primary breast tumors. Treatment with the methyltransferase inhibitor 5-Aza-CdR partially reversed the DNA methylation state, and restored RARb transcription, thus indicating that DNA methylation is at least one factor contributing to RARb inactivity. However, the available data indicate that DNA methylation is only a component of the observed RARb gene inactivity. Very likely, RAinducibility of RARb gene is in¯uenced by modi®ca-tions altering RARb2 chromatin, produced by the nuclear receptors that act at bRARE (RARa and the same RARb), as well as DNA methylation.
Results
The RARb2 promoter is methylated in breast cancer cell lines independently of their ER status and RA-inducibility RARb transcription was ®rst tested in a panel of breast cancer cell lines grown in the absence of exogenous RA, by reverse transcriptase-PCR (RT ± PCR), using primers encompassing exons 5 and 6 (de The ' et al., 1990; van der Leede et al., 1992; Toulouse et al., 1997) . Under these conditions, only one cell line, Hs578t, produced a detectable 256 bp RT ± PCR product ( Figure 4a ). Thus, we con®rmed previous reports that RARb gene expression is down regulated/lost in breast cancer cell lines. Growing cells in the presence of RA can assess the distinction between downregulation and loss. As previously reported (Swisshelm et al., 1994; Liu et al., 1997; Shang et al., 1999) , we observed induction of RARb expression and growth inhibition in T47D, MDA-MB-435, MCF7 and ZR75-1 cell lines treated for 48 h with 1 mM RA, but not in the MDA-MB-231 and MDA-MB-468 cell lines.
To see whether the RARb2 methylation status correlated with the ER status, we examined the methylation status at RARb2 in a panel of ER-positive (MCF7, T47D, ZR75-1) and ER-negative (Hs578t, MDA-MB-231, MDA-MB-435, MDA-MB-468) cell lines.
By Southern blotting we analysed the CpG island of the RARb2 promoter within a 7.5 kb XbaI DNA fragment encompassing the TATA box, the bRARE, the transcriptional start site (TS) and the 5' untranslated region of exon 5 (Figure 1a ). In this region we can identify nine HpaII sites (Shen et al., 1991; Baust et al., 1996) . The DNA methylation status was analysed by using the methylation-sensitive enzyme, HpaII ( Figure  1b) . MspI, the isoschizomer of HpaII, insensitive to methylation, was used as a positive control. The PCR probe spans the bRARE and the TATA box regions (Figure 1a) . The same 7.5 kb region was previously analysed in a colon carcinoma cell line, and the size of all the possible fragments relative to the most 3'HpaII site were reported (Cote' and Momparler, 1997) . A representative blot is shown in Figure 1b . Genomic DNA from the ER-positive, RA-inducible cell line T47D is digested to completion, indicating that it is not methylated at any of the HpaII sites. In contrast, DNA from the ER-positive, RA-inducible ZR75-1 cell line and DNA from the ER-negative, RA-resistant MDA-MB-231 cell line showed to be dierentially methylated at the methylation-sensitive sites. (Figure 1b) . Using methylation-speci®c PCR (MSP), we further analysed a 616 bp long RARb2 region from nucleotide 481 to nucleotide 1096 (Shen et al., 1991) in all the cell lines. MSP entails the modi®cation of genomic DNA by sodium bisul®te that converts all unmethylated, but not methylated, cytosine to uracil (Herman et al., 1996) . The distribution of CpGs expected after Na bisul®te modi®cation and the four MSP primers (1 ± 4) is reported in Figure 2a . The genomic DNAs from four breast cancer cell lines ZR751, MCF7, MDA-MB-231, MDA-MB-468 showed partial to complete methylation of the promoter region ( Figure  2b ). The human mammary epithelial cell (HMEC) strain 48R, expressing RARb and three breast cancer cell lines, the RARb-positive Hs578t and the RA-inducible MDA-MB-435 and T47D, revealed only the (U) unmethylated PCR products (Figure 2b) .
These results indicate that hypermethylation of the RARb2 promoter occurs in breast cancer cell lines irrespective of the ER status, and can be detected in both RA-inducible, and RA-resistant breast cancer cells.
RARb2 is unmethylated in both mortal and immortalized HMEC, but is methylated in primary breast tumors Next, we asked whether hypermethylation of RARb2 promoter in cell lines has correlates in clinical breast cancer. As a normal control we analysed the HMEC mortal strains (48R, 172R), that are the closest representation of normal mammary epithelial cells available. We also analysed two immortal mammary epithelial strains (184A1 and 184B5). The DNA of these strains was found to be unmethylated ( Figure 2c ). Consequently, methylation of RARb2 may be an event in the progression of breast cancer, following immortalization. Genomic DNAs from three paranated samples of breast tumors, two ER-positive (T1, T2) and one ER-negative (T3), estimated to contain more than 90% tumor cells, were analysed with all MSP primer pairs, and shown to be partially methylated ( Figure 2d ). Both microdissected breast stroma, and microdissected normal epithelial cells were found unmethylated at RARb2 (our unpublished observations), making it very likely that the U products in the tumor samples were ampli®ed either from residual normal epithelial cells, or stromal cells mixed to tumor cells. DNAs from matching histologically tumor free lymph node samples (N1 ± N3), were similarly analysed and produced only the unmethylated PCR products (Figure 2d ). The DNA of additional 21 tumors was performed using two sets of primer pairs (U3/M3 and U4/M4). Fifteen (7 ER-positive and 8 ER-negative) of the 24 tumors presented methylation at the RARb2 promoter. With the same primer sets hypermethylation at RARb2 was detected in the DNA of ten out of 39 primary breast tumors collected, and analysed independently, at the Johns Hopkins University.
The overall data indicate that hypermethylation at RARb2 promoter occurs in approximately one third of primary breast tumors, and that the RARb2 methylation state is independent of the ER status of the tumor. (Figure 4b ). We asked whether reactivation of RARb expression by 5-Aza-CdR A-resistant cells could be enhanced by RA. By using nonquantitative RT ± PCR, we could not appreciate a dierence in the level of RARb transcription in MDA-MB-231 cells treated with 0.4 mM 5-Aza-CdR alone, or in combination, with 1 mM RA (Figure 4c ). In this experiment, 5-Aza-CdR alone, or in combination with RA, produced 63 and 96% growth inhibition respectively. In the same experiment, treatment with 1 mM RA alone produced a negligible eect on growth inhibition (52%). A synergistic eect of the two drugs on cancer cells was previously reported (Cote' and Momparler, 1997; Bovenzi et al., 1999) .
5-Aza-CdR induces partial demethylation at the
These data indicate that DNA methylation is, at least, one factor in¯uencing the downregulation/loss of RARb transcription in breast cancer cell lines with a methylated RARb2 promoter. Cells treated with 5-Aza-CdR alone, or in combination with RA, showed re-expression of RARb, which may have contributed, along with the toxic 5-Aza-CdR, to the observed growth inhibition.
The HDAC inhibitor TSA can reactivate RARb expression in RA-resistant cells; demethylation of the RARb2 promoter is not an absolute requirement for RARb reactivation
The chromatin status at a given locus can be dynamically in¯uenced by the degree of acetylation/ deacetylation due to HAT/HDAC activities. Absence of RARb regulatory factors, like RARa, as well as DNA-methylation, can contribute to pattern chromatin modi®cations at RARb promoter in RA-resistant cell lines. One of these cell lines, MDA-MB-231, lacks RAinducible RARa activity (Shao et al., 1994) and displays a RARb2 methylated promoter. We decided to probe indirectly whether the level of HDAC at RARb2 can in¯uence RARb expression, by testing the eect of TSA, a HDAC inhibitor on MDA-MB-231 cells (Yoshida et al., 1995) . Cells were treated for 2 days, in the presence or absence of 100 ng/ml TSA alone, or in combination, with 1 mM RA. By using RT ± PCR, it was clear that, unlike cells treated with RA alone, cells treated with a combination of RA and TSA re-expressed RARb mRNA (Figure 4d ). Under the same experimental conditions, 100 ng/ml TSA alone, or in combination with 1 mM RA, produced 77 and 92% growth inhibition, respectively. Treatment with 1 mM RA alone did not aect signi®cantly growth inhibition (52%). By MSP analysis, we could assess that RARb expression was restored in the presence of a methylated RARb2 promoter. The MSP pro®le obtained with primer set 3, spanning the bRARE region is reported in Figure 5 . This ®nding indirectly shows that global alterations of HDAC activity, generated by TSA in MDA-MB-231 cells, involved RARb2 resulting in RA-induced RARb expression. Further, demethylation at RARb2 did not seem to be an absolute requirement for RARb gene expression in MDA-MB-231 cells. Noteworthy, persistence of methylation at RARb2 was observed also in MCF7 cells where RARb transcription could be restored in the presence of RA (data not shown). Growth inhibition was observed in cells treated with TSA alone, or in combination, with RA. Very likely, RARb along with TSA, a drug known to induce growth inhibition (Yoshida et al., 1995) , contributed to the massive growth inhibitory eect that we observed.
Discussion

RARb2 promoter is methylated in breast cancer
In this study, we show evidence that, in breast cancer cells, RARb2 promoter undergoes DNA hypermethylation, an epigenetic change known to induce chromatin modi®cations and in¯uence gene expression (Razin, 1998; Ng and Bird, 1999; Jones and Wole, 1999) . We detected methylation of the RARb2 promoter region, both in breast carcinoma cell lines, and a signi®cant proportion of primary breast tumors. RARb2 methylation status did not correlate with the ER status of breast cancer cells and was observed both in in situ lesions and invasive tumors (our unpublished observations).
It is not clear when epigenetic changes occur during breast cancer progression. However, methylation of the promoter was not detected in both mortal, and immortal human mammary epithelial cell (HMEC) strains, as well as in normal microdissected breast epithelial cells (our unpublished observations). These results suggest that aberrant methylation of the RARb2 CpG island may be a later event following immortalization. Treatment of breast cancer cells presenting with a methylated RARb2, with the demethylating agent 5-Aza-CdR, induced partial DNA demethylation and restored RARb gene expression. This evidence clearly indicates that DNA methylation is at least a component contributing to RARb downregulation/loss.
RARb2 methylation state and RA-inducibility
The correlation between RARb2 methylation and RAinducibility in dierent breast cancer cell lines, indicates that DNA methylation is not the only factor in¯uencing RARb silencing. Survey of dierent breast cancer cell lines shows that RARb is downregulated, but can be reinduced by RA both in MDA-MB-435 and T47D cells, with unmethylated RARb2 promoter and in MCF7 and ZR751 cells, with a methylated promoter. In contrast, in MDA-MB-231 and MDA-MB-468 cell lines the methylated RARb2 promoter is indierent to RA treatment. Apparently, dierent degrees of repression can aect RARb2 promoter, and only in some cases, the ligand is sucient to alleviate methyl-directed repression. Extinction of RARb transcription must be determined by a stable repressive state in the chromatin structure determined by more than one mechanism, including DNA methylation.
DNA-methylation might be secondary to RARb2 promoter inactivity
We hypothesize that low intracellular levels of RA in breast cancer cells may induce chromatin structure alterations at RARb2, similar to the ones observed in the P19 embryonal carcinoma cell line . Although the mechanism of chromatin structure alterations are not fully understood, current evidence indicates that local histone acetylation is a crucial factor (Razin, 1998 ). An altered chromatin environment may predispose to DNA methylation, a condition that might further aect histone deacetylation at RARb2 (Razin, 1998; Ng and Bird, 1999; Jones and Wole, 1999) . The ®rst to propose that gene inactivity`invites' de novo methylation was Bird (1986) . The hypothesis was further re®ned, after the discovery of the mechanistic link between DNA methylation and chromatin conformation mediated by the MeCP2/ Sin3A/HDAC corepressor complex (Nan et al., 1998; Wade et al., 1998) . According to the revisited hypothesis, Ng and Bird (1999) propose that:`DNA methyltransferase ± either independently or assisted by accessory proteins ± may be capable of reading the histone acetylation pattern on the chromatin and its de novo methyltransferase activity can respond dierentially to dierent states of chromatin modi®cation. In this case, deacetylated chromatin would provoke de novo methylation. This self-reinforcing mechanism, supported by DNA methylation and histone deacetylation, could provide a stable state of inactive chromatin, unless overcome by other mechanisms'.
RARb2 promoter in breast cancer might provide an ideal system to test this hypothesis, given the heterogeneous correlation between its methylation state and RA-inducibility in dierent breast cancer cells. Unmethylated, RA-inducible RARb2 promoters are expected to be associated with, either an active chromatin state, or a mild repressive state. A methylated RARb2 promoter is expected to be associated with a more repressive chromatin environment. As a consequence, transcription from a methylated promoter should be possible, either by recruiting consistent HAT activity, or by inhibiting excessive HDAC activity. These speculations are so far supported by compelling circumstantial evidence. Notably, RA can induce both RARa and RARb in MCF7 cells from a RARb2 methylated promoter (Shao et al., 1994; Shang et al., 1999; our unpublished observations) . This suggests that RA may trigger recruitment of HAT activity at RARb2, sucient to override methylation-related chromatin constraints. On the contrary, in the MDA-MB-231 cells we saw that RA-induced RARb transcription is possible after treatment with TSA, a HDAC inhibitor, already known to induce chromatin alterations at RARb2 promoter in P19 cells . Analysis of the DNaseI sensitivity pattern, in and around RARb2, as well as the assessment of RARb2 histone acetylation state (Keshet et al., 1986; Hebbes et al., 1994; Eden et al., 1998) , in both MCF7 and MDA-MB-231 cells will give us an idea of the relation between chromatin environments and RARb transcription. Moreover, these studies are expected to shed light on the relation of histone acetylation and methylation of the RARb2 promoter. This issue is of particular interest since it is not yet completely clear whether DNA demethylation is indeed always required to restore transcription from genes with fully methylated promoters (Cameron et al., 1999; Ferguson et al., 1998; Razin, 1998; Ng and Bird, 1999) .
In conclusion, we provide evidence that DNAmethylation at RARb2 promoter in breast cancer cells is aecting, at least in part, RARb transcription. We argue that DNA-methylation is secondary to the inactive state at RARb2 promoter and may contribute to create a stable repressive RARb2 environment and extinction of RARb transcription. Further understanding of epigenetic changes and chromatin alteration at RARb2 may have preventive and therapeutic implications. Changes altering RARb2 chromatin structure and RARb transcription in breast cancer might be prevented in the presence of supraphysiological levels of RA (Minna and Mangeldorf, 1997) . Knowledge of RARb2-methylation state of primary breast cancers might be useful to identify tumors that are more likely to respond to RA-therapy. Finally, the possibility to re-induce RARb activity in RA-resistant breast cancer cells, using both TSA and RA, a combination proven to be eective for treating leukemia (Grignani et al., 1998; Guidez et al., 1998; Lin et al., 1998; Warrell et al., 1998) , might have therapeutic implications also in the treatment of RA-resistant breast tumors.
Materials and methods
Cell cultures
Human epithelial mammary cells (HEMC) from reduction mammoplasty including three mortal strains, 184, 48R and 172R, and two immortal strains, 184A1 and 184B5, were obtained and cultured according to the protocols designed by Dr Martha Stampfer (see the HMEC Homepage, http:// www.lbl.gov/*mrgs/index.htlm) using Clonetics (Walkersville, MD, USA) reagents.
Human breast cancer cell lines were maintained in Dulbecco's modi®ed Eagle's medium (GIBCO) (Hs578t, MCF-7, MDA-MB-231 and T47D) or IMEM medium (Bio¯uids) (MDA-MB-435, MDA-MB-468, ZR751) with 5% fetal calf serum (FCS). For drug treatments, exponentially growing cells were seeded in 10 cm 2 plates at a density of 3610 5 cells/plate or in 6-well plates at 1610 5 cells/well. Cells were allowed to attach overnight before the addition of the appropriate concentration of 5-Aza-2' deoxycytidine (5-Aza-CdR) (Sigma), Trichostatin A (TSA) (Sigma) or RA (Sigma). When reduction of retinoids was required, cells were treated in either medium with 0.5% FCS or charcoal-dextran stripped FCS (Hyclone). At the indicated time points, both attached and detached cells were harvested, counted with Trypan Blue (Life Technologies) and processed for DNA or RNA extraction. 5-Aza-CdR was dissolved in 0.45% NaCl containing 10 mM sodium phosphate (pH 6.8). Trichostatin A and all-trans-retinoic acid (RA) (Sigma) were reconstituted in absolute ethanol (solvent). The growth inhibition (%) was calculated as: (1-NT/NC)6100, where NT is the number of treated cells and NC is the number of control cells.
Tissue samples
Normal and tumor tissues were collected from existing tumor banks (Instituto per lo Studio e la Cura dei Tumori, Milan; the Cancer Center, Rotterdam, the Johns Hopkins Breast Cancer Program, Baltimore, MD, USA). All tumor samples were obtained from excess clinical specimens and institutional guidelines for the acquisition and maintenance of such specimens were followed.
DNA and RNA extraction
Extraction of DNA and RNA from breast cancer cell lines was performed by using DNAzol and Trizol respectively (Life Technologies) according to the manufacturer's instructions. Genomic DNA was further treated with 500 mg/ml proteinase K at 558C, extracted with phenol-chloroform-isoamylic alcohol (24 : 24 : 1) (CIA) and ethanol precipitated. Extraction of DNA from paranated breast cancer and lymph node tissues was essentially performed as previously described (Formantici et al., 1999) . One to three consecutive sections estimated to contain at least 90% tumor cells were incubated at 588C overnight in 200 ml of extraction buer (50 mM KCl, 10 mM Tris-HCl (pH 7.5), 2.5 mM MgCl 2 , 0.1 mg/ml gelatin, 0.45% NP-40, 0.45% Tween 20, and the solution was heated at 958C for 15 min to inactivate the proteinase K and then centrifuged at 6000 r.p.m. The DNA in the supernatant was used for analysis.
Southern blotting
Genomic DNA (7 mg) was digested overnight with 15 U/mg of XbaI, HpaII and MspI enzymes, electrophoresis on a 0.8% agarose gel and transferred to Hybond-N ®lter. A 227 bp probe was ampli®ed using the sense 5'-AGA GTT TGA TGG AGT TGG GTG GAG-3' and antisense 5'-CAT TCG GTT TGG GTC AAT CCA CTG-3' primers, gel puri®ed and labeled with 32 P-dCTP using the Megaprime DNA labeling system (Amersham). After hybridization the ®lters were washed and exposed to X-ray ®lm at 7808C for autoradiography.
Methylation specific PCR (MSP)
Bisul®te modi®cation of genomic DNA was essentially performed as described by Herman et al. (1996) . Modi®ed DNA was used immediately or stored in aliquots at 7208C. The PCR mixture contained 16PCR buer (16.6 mM ammonium sulfate, 67 mM Tris (pH 8.7), 1.5 mM MgCl 2 ), dNTPs (each at 1.25 mM), primers (300 ng each per reaction), and bisul®te-modi®ed DNA (50 ng) or unmodi®ed DNA (50 ng). Reactions were hot started at 958C before the addition of 2.5 U of Taq polymerase (Qiagen). Ampli®cation was carried out in a Thermal Cycler 480 Perkin Elmer for 30 cycles (1 min at 948C, 1 min at the annealing temperature (at) selected for each primer pair, 1 min at 728C), followed by 4 min at 728C. Twelve ml of the PCR reaction were electrophoresed onto 1.5% agarose gels, stained with ethidium bromide and visualized under UV. Two primer pairs, W3 sense 5'-CAGCCCGGGTAGGGTTCACC-3', W3 antisense 5'-CCGGATCCTACCCCGACGG-3', and W4 sense 5'-CCGAGAACGCGAGCGATCC-3' and W4 antisense 5'-GGCCAATCCAGCCGGGGCG-3', were designed on the human RARb2 sequence (Shen et al., 1991) and used to control the Na bisul®te modi®cation. The primer pairs selected to detect the unmethylated DNA were as follows: U1 sense 5'-GTG GGT GTA GGT GGA ATA TT-3' and U1 antisense 5'-AAC AAA CAC ACA AAC CAA CA-3' (at 558C); U2 sense 5'-TGT GAG TTA GGA GTA GTG TTT T-3' and U2 antisense 5'-TTC AAT AAA CCC TAC CCA-3' (at 498C); U3 sense 5'-TTA GTA GTT TGG GTA GGG TTT ATT-3' and U3 antisense 5'-CCA AAT CCT ACC CCA ACA-3' (at 558C); U4 sense 5'-GAT GTT GAG AAT GTG AGT GAT TT-3' and U4 antisense 5'-AAC CAA TCC AAC CAA AAC A-3' (at 558C); The sequences of the primers to detect the methylated DNA were: M1 sense 5'-AGC GGG CGT AGG CGG AAT ATC-3' and M1 antisense 5'-CAA CGA ACG CAC AAA CCG ACG-3' (at 638C); M2 sense 5'-CGT GAG TTA GGA GTA GCG TTT C-3' and M2 antisense 5'-CTT TCG ATA AAC CCT ACC CG-3' (at 578C); M3 sense 5'-GGT TAG TAG TTC GGG TAG GGT TTA TC-3' and M3 antisense 5'-CCG AAT CCT ACC CCG ACG-3' (at 648C); M4 sense 5'-GTC GAG AAC GCG AGC GAT TC-3' and M4 antisense 5'-CGA CCA ATC CAA CCG AAA CG-3' (at 648C).
The distrubution of the CpG methylated sites and the position of the primers is reported in Figure 2 . M and U primers were designed in the same regions, with one or two nucleotide dierences to meet annealing requirements. Fragment M3 (position 773 ± 1007) contains the bRARE (792 ± 808) and the transcription start site (position 844); fragment M4 (position 949 ± 1096) contains an Sp1 element (position 1074 ± 1081).
RT ± PCR
The exon 5 (sense primer 5'-GAC TGT ATG GAT GTT CTG TCA G-3') and exon 6 (antisense primer 5'-ATT TGT CCT GGC AGA CGA AGC A-3') were designed on the basis of published RARb2 transcript (de The' et al., 1990; van der Leede et al., 1992) and used to amplify 50 ng of DNase treated total RNA using the Superscript One-Step RT ± PCR System (Life Technologies). RT ± PCR with actin primers (sense primer 5'-ACC ATG GAT GAT GAT ATC G-3' and antisense primer 5'-ACA TGG CTG GGG TGT TGA AG-3' was used as an internal RNA control.
